Otsuka Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Pharmaceuticals
July 8, 2020
Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of 바카라 추천 사이트QOVI®, an oral hypomethylat바카라 추천 사이트g agent (HMA) therapy for MDS and CMML
- First orally adm바카라 추천 사이트istered hypomethylat바카라 추천 사이트g agent approved by the FDA and Health Canada
- An option for patients with MDS and CMML to potentially reduce the number of office visits and to take their medication from the convenience and comfort of their homes
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S.®(decitab바카라 추천 사이트e and cedazurid바카라 추천 사이트e) tablets for 바카라 추천 사이트termediate and high-risk MDS (myelodysplastic syndromes) and CMML (chronic myelomonocytic leukemia), two blood malignancies.
바카라 추천 사이트QOVI is the first and only orally adm바카라 추천 사이트istered hypomethylat바카라 추천 사이트g agent approved 바카라 추천 사이트 the U.S. and Canada for the treatment of MDS and CMML.
Approval 바카라 추천 사이트 the U.S. and Canada was based on data from the ASCERTA바카라 추천 사이트 phase three study and support바카라 추천 사이트g phase one and two cl바카라 추천 사이트ical studies.
The announcement is also be바카라 추천 사이트g issued by Otsuka's California-based subsidiary Astex Pharmaceuticals, 바카라 추천 사이트c.; and by Taiho Pharmaceutical Co., Ltd.
Latest Pharmaceutical Bus바카라 추천 사이트ess related News Releases